London – Paul Hastings LLP, a leading global law firm, today announced it has advised Investcorp, a leading global provider and manager of alternative investment products, on its acquisition of Sanos Group, a leading provider of specialised clinical trial services to the global pharmaceutical and biotechnology industry.
The acquisition will allow Investcorp to support Sanos Group’s efforts to capitalise on its multiple market opportunities by further increasing its penetration in osteoarthritis, while looking to grow into clinical trials for other therapeutic areas and expanding its research clinics network into new geographies.
The team was led by Peter Hayes, Partner in the Leveraged Finance practice at the firm’s London office, with associates Alon Blitz and Michelle Li assisting.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognised as one of the world’s most innovative global law firms.